title: Management of renal cancer in the tyrosine kinase inhibitor era: a view from 3 years on.
abstract: In the last 3 years there has been a dramatic increase in the treatment options for patients with metastatic renal cancer. In addition to the cytokines interferon and interleukin 2, recently approved agents include sorafenib, sunitinib, temsirolimus and bevacizumab. A plethora of agents that are likely to have clinical activity are currently in the development 'pipeline'. This brief review is intended to overview recent developments, and to identify advances that are likely to influence treatment decisions.
authors.affiliation: Section of Melanoma, Renal Cancer and Immunotherapy, The Nevada Cancer Institute, Las Vegas, NV 89135, USA. wsamlowski@nvcancer.org
authors.forename: Wolfram E
authors.initials: WE
authors.lastname: Samlowski
authors.forename: Bryan
authors.initials: B
authors.lastname: Wong
authors.forename: Nicholas J
authors.initials: NJ
authors.lastname: Vogelzang
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*
chemical_list: D000970:Antineoplastic Agents; D011505:Protein-Tyrosine Kinases